24/7 Market News Snapshot 07 May, 2025 – Hepion Pharmaceuticals, Inc. Common Stock (NASDAQ:HEPA)

May 7, 2025

DENVER, Colo., 07 May, 2025 (www.247marketnews.com) – (NASDAQ:HEPA) are discussed in this article.
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) is experiencing a significant surge in the pre-market session, with its stock trading at $0.396, representing a notable increase of 22.26% from the previous close of $0.324. This surge has been accompanied by a robust trading volume of 5.62 million shares, reflecting strong investor interest and bullish market sentiment towards the company’s innovative therapies. Market analysts suggest that this upward momentum could persist, presenting a compelling opportunity for investors as Hepion positions itself for growth in the biotechnology sector.

In a strategic move to enhance its offerings, Hepion has also entered into a binding letter of intent (LOI) with New Day Diagnostics LLC, aimed at in-licensing a suite of advanced diagnostic tests. This partnership targets critical areas such as celiac disease, respiratory multiplex infections, helicobacter pylori (H. pylori), and hepatocellular carcinoma (HCC). The combined addressable market for these diagnostic tests exceeds $15 billion, indicating substantial commercial potential.

Among the diagnostic tools included, the Respiratory Panel RT-PCR Multiplex CE-IVD, which enables simultaneous testing for COVID-19, Influenza A/B, and RSV, addresses a significant market valued at $5.6 billion. Furthermore, the CE-IVD test for H. pylori targets a $700 million market, while the rapid test for celiac disease is poised to impact a $457 million sector. In addition, the mSEPT9 assay presents an opportunity in the $8.7 billion market for early detection of HCC.

John Brancaccio, Executive Chairman and Interim Chief Executive Officer of Hepion, expressed optimism regarding the collaboration, emphasizing its alignment with the company’s growth strategy and potential for near-term revenue generation through established distributor networks. Eric Mayer, CEO of New Day Diagnostics, echoed this sentiment, noting the mutual goal of improving patient outcomes through enhanced early detection methodologies. This partnership signifies a key development for Hepion as it continues to advance in the biopharmaceutical landscape while addressing unmet medical needs.

Related news for (HEPA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.